Gray R H, de la Iglesia F A
Hepatology. 1984 May-Jun;4(3):520-30. doi: 10.1002/hep.1840040328.
Peroxisome proliferation, a well-documented subcellular reaction which follows the administration of hypolipidemic agents, has been well studied in rodents. However, quantitative studies of this phenomenon in other species of laboratory animals are not readily available even though these species are commonly used as predictors of tolerance or safety in humans. The quantitative stereologic studies reported here compared the effects of the new hypolipidemic agent gemfibrozil on hepatic peroxisomes of monkeys, dogs, hamsters and rats of both sexes under several treatment schedules. Gemfibrozil was administered to rats at 300 mg per kg per day for 1 year in the diet; to hamsters at 400 mg per kg per day for 2 weeks by diet admixture; to dogs at 300 mg per kg per day in gelatin capsules for 1 year; and to monkeys at 300 mg per kg day for 3 months by gavage. These dose levels were selected on the basis of tolerance from preliminary studies in each species. At the end of each experimental interval, liver samples were processed for quantitative microscopy. Peroxisomes from male rats were enlarged and the number of peroxisomes per cell were increased 7-fold over controls, resulting in a 20-fold increased peroxisome volume per cell. Statistically, significant increases also occurred in female rats and the difference between treated and controls was 3-fold for both number and volume of peroxisomes per cytoplasmic unit volume. In hamsters, peroxisomes were proliferated and were of significantly smaller size to the extent that the volume of cytoplasm occupied by peroxisomes was not significantly changed. In dogs, the number of peroxisomes per cell was increased and the volume fraction was significantly increased in females only. The number of peroxisomes in young monkeys did not change after treatment, and the peroxisome volume was decreased in males and increased in females. Aged monkeys had increased number of peroxisomes per hepatocyte with increased volume fraction. These results indicate significant differences in the magnitude and direction of peroxisome changes, reflecting species-dependent organelle response to hypolipidemic agents. The order of susceptibility of peroxisome proliferation in laboratory animals is dog less than monkey less than hamster less than rat.
过氧化物酶体增殖是一种在给予降血脂药物后有充分记录的亚细胞反应,在啮齿动物中已得到充分研究。然而,即使这些物种通常被用作人类耐受性或安全性的预测指标,对其他实验动物物种中这一现象的定量研究也并不容易获得。本文报道的定量体视学研究比较了新型降血脂药物吉非贝齐在几种治疗方案下对雄性和雌性猴子、狗、仓鼠和大鼠肝脏过氧化物酶体的影响。吉非贝齐通过饮食给予大鼠,剂量为每天300毫克/千克,持续1年;通过饮食混合给予仓鼠,剂量为每天400毫克/千克,持续2周;通过明胶胶囊给予狗,剂量为每天300毫克/千克,持续1年;通过灌胃给予猴子,剂量为每天300毫克/千克,持续3个月。这些剂量水平是根据每个物种初步研究的耐受性选择的。在每个实验间隔结束时,对肝脏样本进行定量显微镜检查。雄性大鼠的过氧化物酶体增大,每个细胞的过氧化物酶体数量比对照组增加了7倍,导致每个细胞的过氧化物酶体体积增加了20倍。从统计学上看,雌性大鼠也出现了显著增加,处理组和对照组之间每个细胞质单位体积的过氧化物酶体数量和体积差异均为3倍。在仓鼠中,过氧化物酶体增殖,且尺寸明显较小,以至于过氧化物酶体占据的细胞质体积没有显著变化。在狗中,每个细胞的过氧化物酶体数量增加,仅雌性的体积分数显著增加。幼年猴子治疗后过氧化物酶体数量没有变化,雄性过氧化物酶体体积减小,雌性增加。老年猴子每个肝细胞的过氧化物酶体数量增加,体积分数增加。这些结果表明过氧化物酶体变化的程度和方向存在显著差异,反映了物种依赖的细胞器对降血脂药物的反应。实验动物中过氧化物酶体增殖的易感性顺序为狗<猴子<仓鼠<大鼠。